NCT02721433View on ClinicalTrials.gov

4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases

PHASE4CompletedINTERVENTIONAL
Enrollment

263

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

September 30, 2019

Study Completion Date

April 30, 2020

Conditions
Breast CancerProstate CancerMetastasis
Interventions
DRUG

Pamidronate

Bone-targeted agent as standard of care

DRUG

Denosumab

Bone-targeted agent as standard of care

DRUG

Zoledronate

Bone-targeted agent as standard of care

Trial Locations (1)

Unknown

The Ottawa Hospital Research Institute, Ottawa

Sponsors
All Listed Sponsors
lead

Ottawa Hospital Research Institute

OTHER